BioCentury | Nov 4, 2020
Product Development

Data Byte: BMS TYK2 inhibitor could set bar for oral efficacy in psoriasis

...data from a second Phase III trial, POETYK PSO-2, are expected in 1Q21. TARGETSPDE-4 – Phosphodiesterase...
BioCentury | Aug 5, 2020
Product Development

I-SPY COVID brings new set of targets to master protocols for acute respiratory distress

...CD192) - CC chemokine receptor 2 CCR5 (CD195) - CC chemokine receptor 5 PDE-4 - Phosphodiesterase-4...
...CD192) CC chemokine receptor 5 (CCR5) (CD195) Tyrosine kinase receptor 2 (Tie2) Protein tyrosine phosphatase receptor type B (PTPRB) Phosphodiesterase-4...
BioCentury | Jul 24, 2020
Finance

Four more biotech IPOs reach the market, but no big first-day pop in the bunch

...crossover investors (see “Piling In” ). Targets ADORA2A - Adenosine A2A receptor ENPP1 - Ectonucleotide pyrophosphatase/phosphodiesterase...
BioCentury | Jul 3, 2020
Finance

On heels of $100M raise, Annexon joins burgeoning IPO queue

...Btk - Bruton’s tyrosine kinase C1q - Complement component 1 q subcomponent ENPP1 - Ectonucleotide pyrophosphatase/phosphodiesterase...
BioCentury | May 28, 2020
Product Development

May 27 Quick Takes: EC approves Zeposia in RRMS; plus Dupixent approved in children, La Jolla, Shionogi, Alnylam and Bold

...5 HAO1 - Hydroxyacid oxidase 1 IL-4 (BSF1) - Interleukin-4 IL-13 - Interleukin-13 PDE-4D - Phosphodiesterase-4D...
...Inc. Sanofi La Jolla Pharmaceutical Co. Shionogi & Co. Ltd. Tetra Therapeutics Alnylam Pharmaceuticals Inc. Hydroxyacid oxidase 1 (HAO1) Interleukin-4 (IL-4) (BSF1) Interleukin-13 (IL-13) Phosphodiesterase-4D...
BioCentury | Apr 10, 2020
Product Development

COVID-19 roundup: New immune targets to address pandemic; plus updates from CanSino, Arcturus, Fujifilm and more

...channel IL-6 - Interleukin-6 MIF - Macrophage migration inhibitory factor PDE-4 - Phosphodiesterase-4 PDE-10 - Phosphodiesterase-10 Sandi...
...Jefferson University MediciNova Inc. CanSino Biologics Inc. Fujifilm Holdings Corp. Calcitonin gene-related peptide (CGRP) receptor Macrophage migration inhibitory factor (MIF) Phosphodiesterase-4 (PDE-4) Phosphodiesterase-10...
BioCentury | Mar 27, 2020
Product Development

March 26 Quick Takes: Pear’s digital therapeutic approved for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax

...MET; HGFR) - c-Met receptor tyrosine kinase LpxC - Bacterial UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase PDE-4 - Phosphodiesterase-4 Hongjiang...
BioCentury | Mar 19, 2020
Emerging Company Profile

OncoOne: targeting oxidized MIF for solid tumors

...investors CEO: Randolf Kerschbaumer Patents: None issued Targets MIF- Macrophage migration inhibitory factor PDE-4 - Phosphodiesterase-4 Lauren...
BioCentury | Mar 13, 2020
Finance

Cratering market spoils Imara’s NASDAQ debut

...to accelerate testing of a delivery device for the vaccine (see “COVID-19 Update” ). Targets Phosphodiesterase-9...
BioCentury | Mar 10, 2020
Product Development

March 9 Quick Takes: A first for Boehringer’s Ofev; plus Cel-Sci’s COVID-19 therapy, Sinopharm, AZ, Urovant, Hengrui, Trevena, and Tetra-Shionogi

...4 FGFR - Fibroblast growth factor receptor MOR (OPRM1) - Mu opioid receptor PDE-4D - Phosphodiesterase-4D...
Items per page:
1 - 10 of 1095